The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy being developed by…
Articles by Andrea Lobo, PhD
Origami Therapeutics is collaborating with Ipsen to develop experimental therapies designed to remove or correct abnormal proteins that…
Target ALS has announced the launch of its redesigned website, which improves accessibility and highlights its research initiatives to…
Dewpoint Therapeutics has selected a novel small molecule designed to prevent the formation of abnormal TDP-43 protein clumps that…
Mindwalk Holdings has identified and validated antibodies that selectively target an abnormal form of the TDP-43 protein, which is…
The first patient has been dosed in a Phase 2 clinical study testing RAG-17, a therapy being developed by…
The first participants have been dosed in an early Phase 1 clinical study that’s testing NRG5051, a first-in-class treatment…
An experimental, noninvasive device for slowing the progression of functional symptoms in people with amyotrophic lateral sclerosis (ALS) has…
A Phase 2 clinical trial to investigate Tiziana Life Sciences’ intranasal foralumab for the treatment of amyotrophic lateral…
Aperture Therapeutics has selected APRTX-001 as its lead candidate to treat amyotrophic lateral sclerosis (ALS) and other neurodegenerative…